Keywords: Nitto Denko, Quark Pharma, siRNA, Anti-fibrotic drug
Nitto Denko and Quark Pharma to collaborate on novel siRNA anti-fibrotic drug
Article | 16 July 2010
Japanese diversified materials manufacturer Nitto Denko and Quark Pharmaceuticals, a US firm specializing in the discovery and development of RNAi-based ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
